The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain

Table 6

Mean and change from baseline in fasting plasma glucose and plasma glucose 2 hours after breakfast (ITT population).

	⁢5-ALA-SFC			⁢Placebo
		Mean	Change from baseline; Mean (SE)		Mean	Change from baseline; Mean (SE)
Fasting plasma glucose (mg/dL)
Week 2	33	145.1	2.3 (3.4)	14	138.4	−7.3 (5.2)
Week 4	30	142.1	−0.2 (4.9)	14	145.6	−0.8 (7.2)
Week 6	27	138.0	−4.8 (3.2)	13	132.4	−9.2 (4.7)
Week 8	22	135.8	−4.5 (4.0)	12	142.7	−1.0 (5.5)
Week 10	23	140.3	−0.9 (5.6)	12	143.1	−0.9 (7.8)
Week 12	22	139.3	−3.0 (4.4)	12	139.5	−4.2 (5.9)
Plasma glucose 2 hours after meal (mg/dL)
Week 2	33	189.6	−0.2 (5.1)	14	166.3	−26.5 (7.8)
Week 4	30	175.7	−12.9 (6.1)	12	173.9	−18.8 (9.9)
Week 6	27	173.4	−14.5 (5.4)	13	158.5	−27.4 (7.8)
Week 8	20	176.2	−5.6 (5.6)	11	155.0	−30.5 (11.2)
Week 10	20	175.1	−10.3 (10.5)	12	181.2	−7.6 (13.5)
Week 12	21	175.0	−8.5 (9.8)	10	154.3	−33.0 (14.2)

< 0.05 between groups.
Compared to baseline mean for only the subjects with a result for the visit.